Godavari Biorefineries Reports ₹23.41 Cr Net Loss in FY25 on Deferred Tax Impact; Revenue Rises 10.9% YoY
By Ankur Chandra | Updated at: May 31, 2025 10:43 PM IST
MUMBAI, May 26, 2025 – Godavari Biorefineries Ltd (NSE: GODAVARIB | BSE: 544279) reported its audited consolidated financial results for the year ended March 31, 2025, posting a net loss of ₹2,341.47 lakh (₹23.41 crore) due to a one-time deferred tax impact of ₹2,449.45 lakh, despite achieving double-digit revenue growth.
FY25 Consolidated Financial Highlights
| Particulars | FY25 (₹ lakh) | FY24 (₹ lakh) | YoY Change |
|---|---|---|---|
| Revenue from Operations | 1,87,025.12 | 1,68,666.53 | +10.9% |
| Total Income | 1,88,691.38 | 1,70,106.42 | +10.9% |
| Total Expenses | 1,88,845.17 | 1,68,861.83 | +11.8% |
| Profit / (Loss) Before Tax | (153.79) | 1,244.59 | — |
| Net Profit / (Loss) after Tax (excl. one-time item) | 107.99 | 1,229.83 | — |
| One-Time Deferred Tax Impact | 2,449.45 | — | — |
| Net Profit / (Loss) for the Year | (2,341.47) | 1,229.83 | — |
| Basic & Diluted EPS (₹) | (5.11) | 2.93 | — |
The company’s EBITDA stood at ₹10,558.42 lakh, up from ₹7,095.02 lakh last year, reflecting strong operational momentum.
Comprehensive Income & Equity Position
Total comprehensive loss for FY25 stood at ₹2,373.87 lakh compared to a gain of ₹1,125.44 lakh in FY24, primarily due to foreign currency translation losses and actuarial adjustments.
Shareholders’ equity surged to ₹78,196.43 lakh from ₹50,067.91 lakh, driven by successful IPO-related capital infusion.
Balance Sheet Snapshot (₹ in lakh)
| Key Metric | FY25 | FY24 |
|---|---|---|
| Total Assets | 1,95,508.90 | 1,99,150.03 |
| Equity Share Capital | 5,117.60 | 4,194.30 |
| Other Equity | 73,078.84 | 45,873.61 |
| Total Liabilities | 1,17,312.47 | 1,49,082.12 |
IPO & Fund Utilization
During FY25, Godavari Biorefineries successfully completed its IPO, raising ₹32,500 lakh:
- ₹24,000 lakh was used for debt repayment.
- ₹6,360.60 lakh for general corporate purposes.
- ₹2,139.40 lakh towards offer-related expenses.
Shares were listed on BSE and NSE on October 30, 2024.
Tax Adjustment Impact
Following amendments under the Finance Act 2024, the company remeasured its deferred tax balances, leading to a one-time deferred tax expense of ₹2,449.45 lakh, which substantially impacted the bottom line.
Management Commentary
Commenting on the results, Chairman and Managing Director Samir Somaiya said:
“Our revenue and operational profitability reflect the resilience of our integrated business model. Despite the accounting impact of deferred taxes, the strong response to our IPO has fortified our balance sheet and will support future growth initiatives.”
Strategic Outlook
The company will continue to focus on margin expansion through capacity enhancement in its sugar, distillery, and bio-based chemical segments. Deleveraging and disciplined capital allocation remain priority areas.
No dividend was declared for FY25.
REF: https://nsearchives.nseindia.com/corporate/GODAVARIBIO_26052025174523_GBL_Revised_Financial_Statements.pdf
